Shattuck Labs, Inc.

NasdaqGS STTK

Shattuck Labs, Inc. Price to Book Ratio (P/B) on January 14, 2025

Shattuck Labs, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Shattuck Labs, Inc. 52-week high Price to Book Ratio (P/B) is 4.05 on May 06, 2024, which is NA below the current Price to Book Ratio (P/B).
Shattuck Labs, Inc. 52-week low Price to Book Ratio (P/B) is 1.15 on August 12, 2024, which is NA below the current Price to Book Ratio (P/B).
Shattuck Labs, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 2.19.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: STTK

Shattuck Labs, Inc.

CEO	Dr. Taylor H. Schreiber M.D., Ph.D.
IPO Date	Oct. 9, 2020
Location	United States
Headquarters	500 West 5th Street
Employees	75
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Key trends

Past 5 years